Deutsche Bank Maintains Buy on Axsome Therapeutics, Lowers Price Target to $267
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Deutsche Bank analyst David Hoang maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $280 to $267.
Deutsche Bank analyst David Hoang maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $280 to $267.